Symic Biomedical is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. Symic's compounds function like proteoglycans, important structural and functional macromolecules native to the ECM (extracellular matrix). The ECM is the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, play a critical role in maintaining tissue function and healing upon injury or in chronic diseases - Symic's molecules function in a similar manner. Symic is targeting the ECM using its proprietary and novel proteoglycan mimics, and will advance its compounds in a variety of acute and chronic therapeutic areas with significant unmet clinical needs.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
01/06/15 | $15,000,000 | Series A |
Ally Bridge Group Den Danske Forskningsfond InCube Ventures Mission Bay Capital Mitsui Global Investment Purdue Foundry Investment Fund QB3 | undisclosed |